# Methotrexate for Central Serous Chorioretinopathy Treatment Trial

> **NCT01633983** · PHASE2 · UNKNOWN · sponsor: **Edward Averbukh** · enrollment: 20 (estimated)

## Conditions studied

- Central Serous Chorioretinopathy

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Delayed treatment

## Key facts

- **NCT ID:** NCT01633983
- **Lead sponsor:** Edward Averbukh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-08
- **Primary completion:** 2014-07
- **Final completion:** 2015-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2012-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01633983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01633983, "Methotrexate for Central Serous Chorioretinopathy Treatment Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01633983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*